Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist)

BACKGROUND: Chemotherapy in platinum-resistant ovarian cancer (PROC) aims for palliation and prolonging of progression-free survival (PFS). This study compares Health-related Quality of Life (HRQoL) and efficacy between single-agent chemotherapy and tamoxifen in PROC. METHODS: Patients with PROC wer...

詳細記述

保存先:
書誌詳細
出版年:Br J Cancer
主要な著者: Lindemann, Kristina, Gibbs, Emma, Åvall-Lundqvist, Elisabeth, dePont Christensen, Rene, Woie, Kathrine, Kalling, Marten, Auranen, Annika, Grenman, Seija, Hoegberg, Thomas, Rosenberg, Per, Skeie-Jensen, Tone, Hjerpe, Elisabet, Dørum, Anne, Gebski, Val, Kristensen, Gunnar
フォーマット: Artigo
言語:Inglês
出版事項: Nature Publishing Group 2017
主題:
Clinical Study
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5318972/
https://ncbi.nlm.nih.gov/pubmed/28118323
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2016.435
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料